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In vitro progesterone production by
luteinized human mural granulosa cells is
modulated by activation of AMPK and
cause of infertility
E. C. Bowdridge2*, M. W. Vernon3, J. A. Flores1 and M. J. Clemmer3
Abstract
Background: Mural granulosa cells from IVF patients were provided by the West Virginia University Center for
Reproductive Medicine in Morgantown, WV. The effect of adenosine monophosphate activated protein kinase
(AMPK) activation, primary cause of infertility, age, BMI, and pregnancy outcome on production of progesterone
were examined separately.
Methods: Isolated mural sheets from IVF patients (n = 26) were centrifuged, supernatant discarded, and the
pellet re-suspended in 500 μl of DMEM/F12. Mural granulosa cells were plated at 10,000 cells/well in triplicate
per treatment group with 300 μl DMEM/F12 media at 37 °C and 5% CO2 in a humidified incubator to permit
luteinization. Four days after initial plating, cells were treated with either an AMPK inhibitor, DM; an AMPK activator,
AICAR; or hCG. Cells were cultured for 24 h after treatment when medium was collected and frozen at −20 °C until
assayed for P4 by radioimmunoassay.
Results: The AMPK activator, AICAR, inhibited P4 production (P < 0.001), whereas the AMPK inhibitor, DM, did not affect
basal P4 (P < 0.05). Progesterone production increased when cells from patients whose primary cause of infertility was a
partner having male infertility were treated with hCG compared to control (P = 0.0045), but not in patients with
other primary infertility factors (P > 0.05). Additionally, hCG increased P4 production in patients between the ages
30–35 (P = 0.008) and 36–39 (P = 0.04), but not in patients ages 25–29 (P = 0.73). Patients with normal BMI had
increased P4 production when treated with hCG (P < 0.0001), however there was no change in P4 production
from cells of patients who were overweight or obese (P > 0.05). Cells from patients who became pregnant to IVF
had greater P4 production when stimulated with hCG than those who did not become pregnant when compared to
controls (P > 0.05).
Conclusions: Understanding how AMPK activation is regulated in ovarian cells could lead to alternative or novel
infertility treatments. Human mural granulosa cells can serve as a valuable model for understanding how AMPK affects
P4 production in steroidogenic cells. Additionally, when stimulated with hCG, P4 production by mural granulosa cells
differed among infertility type, age, BMI, and pregnancy outcome.
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Background
Two distinct populations of granulosa cells exist within
the ovulatory follicle, the mural granulosa cells that line
the follicle and the cumulus granulosa cells that surround
the oocyte. After ovulation, mural granulosa cells remain
in the follicle while cumulus granulosa cells are expelled
from the follicle with the oocyte [19]. The mural granulosa
cells that remain in the ovulatory follicle lose their ability
to proliferate and to produce estradiol. Under the influ-
ence of the LH surge which induced the ovulation, the
mural cells undergo an epithelial-mesenchymal transition
that leads to the formation of the large luteal cells (LLC)
of the corpus luteum [CL], which secrete high amounts of
progesterone [P4] [6]. In the presence of human chorionic
gonadotropin [hCG] from a conceptus, the CL is rescued
from luteolysis and maintains its production of P4, which
is essential for the maintenance of pregnancy. Insufficient
luteal rescue may lead to decreased P4 production that
can lead to pregnancy loss. Luteal insufficiency has been
estimated to be as high as 28% in couples with recurrent
pregnancy loss [14, 15]. A better understanding of insuffi-
cient luteal rescue could improve the clinical diagnosis
and treatment of early pregnancy loss.
In multiple species, sufficient energy is required for P4
production [23, 24]. Adenosine monophosphate acti-
vated protein kinase [AMPK] is a key regulatory protein
for energy balance, and activation of AMPK results in a
shift from anabolic to catabolic processes [11]. In rat
granulosa cells, P4 was directly inhibited by AMPK
activation [25]. Various subunits of AMPK have also
been identified in the granulosa cells of small and large
bovine follicles [23]. 5-Aminoimidazole-4-carboxamide-
1-β-4-ribofuranoside [AICAR] is a well-established,
cell-permeable agent, which both directly activates AMPK
alloterically and promotes phosphorylation of AMPK [7].
Treatment with AICAR (7.5 mM) significantly decreased
basal P4 production in bovine CL in vitro [4]. In contrast,
dorsomorphin dihydrochloride (DM) is a potent, selective,
cell-permeable and reversible AMPK inhibitor [17]. Treat-
ment with DM inhibited AMPK activation induced by
AICAR [22] or metformin [12].
The objectives of this project were to investigate the
role of AMPK, a known intracellular mediator of energy
balance, and a patient’s primary cause of infertility on the
production of P4 in luteinized human granulosa cells.
Methods
Patients
Mural and cumulus granulosa cells from patients (n = 26)
undergoing egg retrieval after ovarian stimulation for in
vitro fertilization [IVF] were provided by the WVU Center
for Reproductive Medicine in Morgantown from April to
December 2012. The age, BMI and primary cause of infer-
tility were random as all patients with granulosa cells
collected at oocyte retrieval were included in the study.
Primary cause of infertility was assigned based on severity
of the problem contributing most to preventing a success-
ful pregnancy for each patient, with preference given to
any issues with the female. Any endocrine related factor,
such as endometriosis, was prioritized as the primary
cause of infertility over any anatomical factor, such as
tubal blockage, because these types of endocrine condi-
tions were more likely to affect the granulosa cells col-
lected for experiments. Patients were designated as male
factor patients if there were no indications of female infer-
tility and the male partner presented with an abnormal
semen evaluation.
Daily or twice-daily injections of recombinant follicle
stimulating hormone [FSH] began on d2 or d3 of the
cycle and continued until ovulation was induced with
hCG. One of the following preparations of FSH was
used: Bravelle (Ferring Pharmaceuticals, Parsippany, NJ),
Gonal F (EMD Serono, Rockland, MD), or Follistim (Merck,
Whitehouse Station, NJ) in addition to Menopur (Ferring
Pharmaceuticals Inc. Parsippany, NJ), which was used for
every patient. Patients returned at least every other day for
sonographic and hormonal monitoring of follicular growth
beginning four days after initiation of stimulation. To
prevent premature ovulation, gonadotropin releasing
hormones [GnRH] antagonist injections (Ganirelix,
Merck, Kenilworth, NJ) began when follicles reached at
least 14 mm in diameter. Ovulation was induced with
hCG injection (10,000 IU; Novarel, Ferring Pharmaceuticals,
Parsippany, NJ) when at least two follicles were ≥18 mm in
diameter, followed by oocyte collection 34 h later.
Isolation and culture of primary human GCs
Sheets of mural granulosa cells were distinguished by
anatomical structure and manually separated from cumulus
granulosa cells by experienced embryologists following
oocyte retrieval. Isolated mural sheets from each patient
in G-MOPS Plus media (Vitrolife, Göteborg, Sweden) were
centrifuged at 10,000 rpm for 5 min at room temperature.
Supernatant was discarded, and the pellet was re-suspended
in 500 μl of DMEM/F12 (Invitrogen, Grand Island, NY)
with 20% (v/v) fetal bovine serum, insulin/transferrin/
selenium B (1000; 555; 0.67 mg/L respectively; Gibco,
Grand Island, NY), gentamicin/amphotericin (10 μg/ml-
0.25 μg/ml; Gibco, Grand Island, NY), and penicillin/strep-
tomyocin (100 I.U./ml, 100 μg/ml; Life Technologies,
Grand Island, NY). Viable cell number was determined using
trypan blue dye exclusion (Gibco, Grand Island, NY) and a
hemocytometer. All patients had cell viability >90% and cells
were plated at 10,000 cells per well in 96-well flat bottom
culture plates with 300 μl DMEM/F12 media (NUNC,
Scientific Laboratory Supplies, Wilford, Nottingham, UK) at
37 °C and 5% CO2 in a humidified incubator to permit lu-
teinization and cell attachment. Media was changed every
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24 h whereby 150 μl of spent media was replaced with fresh
DMEM/F12 plus serum. Peak progesterone levels in human
mural granulosa cells have been shown to occur on day 4 of
culture [1], as was the case during preliminary testing of our
culture conditions of days of luteinization ranging from
1 to 7 (data not shown), and therefore used as the ex-
perimental day. Four days after collection, cells were
transferred to serum free DMEM/F12 media, and treat-
ments were administered. Every treatment was tested in
triplicate for each patient and media pooled for P4 by
radioimmunoassay [RIA] as previously described [20].
Control values for each patient were obtained by cul-
turing cells in triplicate with no hormones. This basal
progesterone production, which was obtained on the
same day as treatments, was used as a baseline for each
patient, and treatments with pharmacological agents or
hormones were compared to baseline within patient.
Experiment 1
Treatments were based on previous studies in bovine
luteal steroidogenic cells [3] and mural granulosa cells. The
medium for the control group contained 0.1% dimethylsuf-
oxide (DMSO, Pierce Rockport, IL), the solvent used for
DM and AICAR. Mural granulosa cells isolated from
patients presenting with tubal or male factor infertility
were used in experiment 1 to control for any confound-
ing female endocrine effect. Mural granulosa cells were
treated with DM (109, 10.9, 1.09, 0.109 μm/L, Tocris,
Bristol, UK) or AICAR (7.5, 0.75, 0.075, 0.0075 mM,
Tocris, Bristol, UK) to evaluate the roles of inhibiting
or stimulating AMPK, respectively, in luteinized mural
granulosa cell production of P4. Cells were cultured for
24 h and medium was removed and frozen at −20 °C
until assayed for P4.
Experiment 2
Cells were treated with PGF2α (0.1 μg/ml; Cayman
Chemical, Ann Arbor, MI), or human hCG (5 IU/ml;
Novarel, Ferring Pharmaceuticals, Parsippany, NJ), or
the combination of the two (PGF2α + hCG). Treatment
concentrations of PGF2α, hCG, or PGF2α + hCG and
incubation times were based on previous studies with
bovine luteal steroidogenic cells [3] and preliminary
studies testing 24, 48, and 96 h incubation times in
mural granulosa cells, respectively. Cells were cultured
further for 24 h after treatment at which time medium
was removed and frozen at −20 °C until assayed for
P4. Main cause of infertility (male factor, endometri-
osis, tubal factor, and unexplained), age (<30, 30–35,
36–39 years of age), BMI (normal = 18.5–24.9, over-
weight = 25–29.9, obese ≥30), and pregnancy outcome
(non-pregnant and pregnant) were analyzed.
Statistical analysis
Concentrations of P4 were tested for normal distribution
via the Shapiro-Wilk test. All data were transformed
using natural logarithm. All other experiments were ana-
lyzed using one-way ANOVA and Dunnett’s post hoc
test. Data were analyzed using JMP and SAS software
(JMP®, Version Pro 11, SAS Institute Inc., Cary, NC,
Copyright ©2013; SAS®, Version 9.3, SAS Institute Inc.,
Cary, NC, Copyright ©2002–2010). Differences were
considered significant when P < 0.05. Data throughout
are depicted as the mean ± SE.
Results
General patient information
Patients presented randomly with the following as their
main cause of infertility: male factor (n = 5), endometriosis
(n = 6), tubal factor (n = 12; n = 11 naturally occurring
tubal issues and n = 1 tubal ligation), and other/unex-
plained (n = 3). They ranged in age from 25 to 39 years of
age (mean age 33.0 ± 0.70) and were classified as <30
(n = 4), 31–35 (n = 15), or ≥36 (n = 7). Patients had a BMI
range of 18.9 to 44.3 (mean BMI 25.0 ± 1.1) and were
classified as normal 18.5–24.9 (n = 17), overweight 25–
29.9 (n = 6) or obese ≥30.0 (n = 3). Most patients (n = 13)
were pregnant after the IVF cycle was completed; 10 did
not become pregnant and the remaining patients (n = 3; 1
no fertilization and 2 planned embryo cryopreservation)
did not receive a fresh embryo transfer at the end of the
IVF cycle. Information about the general response of these
patients to stimulation and IVF are recorded in Table 1.
Experiment 1
To more deeply understand production of progesterone
in luteinized granulosa cells, the pathway involved in
Table 1 General patient information
Patient Information n Range Mean
Age 26 25–39 33 ± 3.58
BMI 26 19–36 24.96 ± 5.50
Gravidity 26 0–9 1.42 ± 2.44
Total Gonadotropins (IU) 26 450–4200 1613 ± 899
Stimulation Days 26 7–12 9.19 ± 1.20
Day 3 FSH (mIU/mL) 20 4–13 7.32 ± 2.16
E2 at trigger (pg/mL) 26 364–3669 1678 ± 837
P4 at trigger (ng/mL) 26 0.43–2.63 1.13 ± 0.68
Total oocytes retrieved 26 2–23 8.4 ± 4.7
MII oocytes retrieved 26 2–18 6.5 ± 3.8
Fertilization rate (%) 26 0–100 82.6 ± 24.5
Division rate (%) 26 67–100 95.8 ± 8.8
Ranges and means for gravidity, stimulation, hormonal profiles, oocytes
retrieved during the IVF cycle, fertilization rate of MII oocytes, and division
rate of fertilized oocytes
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energy regulation was manipulated. The AMPK activator,
AICAR, inhibited P4 production by human luteinized
mural granulosa cells at all dosages tested (P < 0.001;
Fig. 1a). In Fig. 1b, the AMPK inhibitor, DM, did not affect
basal progesterone production (P < 0.05).
Experiment 2
Within cause of infertilty, no significant differences in
P4 were seen when granulosa cells were treated with
PGF2α or PGF2α + hCG in any infertility types (data not
shown), with the exception of male infertility, (control
P4 = 0.77 ± 0.24 ng/ml vs. GF2α = 1.56 ± 0.68 ng/ml;
P < 0.05) Additionally, no significant differences in P4
were seen when granulosa cells were treated with PGF2α
or PGF2α + hCG in any age or BMI category, or preg-
nancy outcome (data not shown).
There was an increase in P4 production over baseline in
cells treated with hCG and collected from patients that
presented with no known female/male infertility factor
(0.77 ± 0.24 ng/ml vs. 2.49 ± 0.38 ng/ml; P = 0.0045;
Fig. 2), but not in patients who presented with endo-
metriosis (1.91 ± 0.87 ng/ml vs. 2.23 ± 1.2 ng/ml),
other/unexplained (1.19 ± 0.80 ng/ml vs. 2.23 ± 0.93 ng/
ml) or tubal factor (1.30 ± 0.36 ng/ml vs. 2.10 ± 0.46 ng/ml;
P > 0.05; Fig. 2).
Additionally, patient age influenced the ability of hCG
to stimulate a significant increase in P4. Production of
P4 increased following treatment with hCG for patients
in the age range of 30–35 (1.23 ± 0.40 ng/ml vs.
2.03 ± 0.46 ng/ml; P = 0.008) and 36–39 (n = 7;
1.41 ± 0.45 ng/ml vs. 2.37 ± 0.53 ng/ml; P = 0.04), but
not in patients in the ranges of 25–29 (n = 4;
1.52 ± 0.75 ng/ml vs. 2.65 ± 0.91 ng/ml; P = 0.73; Fig. 3).
Patients with normal BMI had a significant increase in
P4 production when treated with hCG (1.29 ± 0.34 ng/ml
vs. 2.25 ± 0.46 ng/ml; P < 0.0001; Fig. 4), but granulosa cells
of patients who were categorized as overweight or obese
did not have a significant increase in P4 production when
stimulated with hCG (1.85 ± 0.63 ng/ml vs. 2.61 ± 0.46 ng/
ml and 0.50 ± 0.18 ng/ml vs. 1.24 ± 0.45 ng/ml, respect-
ively; P > 0.05; Fig. 4).
Figure 5 demonstrates that granulosa cells from patients
who became pregnant to the IVF cycle had significantly
increased P4 production compared to controls when stim-
ulated with hCG (2.4 ± 0.37 ng/ml; P = 0.0018 vs. control;
Fig. 4) whereas those who did not become pregnant did
not (1.8 ± 0.58 ng/ml; P > 0.05 vs. control; Fig. 5).
Discussion
Activation of AMPK, a key regulator of energy homeostasis,
decreased basal P4 production in bovine [23] and rodent
[25] granulosa cells, whereas AMPK increased P4 in galline
[24] granulosa cells. In agreement with the findings in cattle
and rats, treatment with AICAR resulted in a significant
decrease in basal P4 at all concentrations tested in experi-
ment 1. Similarly, AICAR treatment resulted in a decrease
in P4 production in the mature bovine CL [4]. This
decrease in P4 could be explained, at least in part, by a
decrease in key enzymes such as 3βHSD, P450scc, or
StAR, all of which have been shown to be decreased
after treatment with AICAR in rat granulosa cells [25].
These experiments show that the AMPK pathway is inhibi-
tory to basal P4 production in luteinized human granulosa
cells in the early stage of luteinization and presumably even
more so with further luteal maturation.
In contrast to the effect of AMPK activation, no differ-
ence in P4 production were seen when mural cells were
treated with an AMPK inhibitor, DM. The concentrations
of DM chosen for Experiment 1 were based on studies in
bovine CL, in which DM significantly decreased P4 produc-
tion following stimulation with PGF2α (Bowdridge, unpub-
lished results). However, a greater concentration of DM
may be needed to elicit a change in basal P4 production in
human mural granulosa cells. Additionally, because DM is
an AMPK inhibitor cells may need to first be stimulated
with hCG, PGF2α, or another AMPK activator prior to DM
treatment in order to see a reduction in P4 production.
Due to the limited number of granulosa cells that are col-
lected from each patient, these experiments were unable to
a
b
Fig. 1 Effect of altering AMPK on progesterone production by
granulosa cells. a The AMPK activator, 5-Aminoimidazole-4-carboxa-
mide-1-β-4-ribofuranoside [AICAR], inhibited progesterone production
by human luteinized mural granulosal cells at all dosages tested. In b, the
AMPK inhibitor, dorsomorphin [DM], did not affect basal progesterone
production. Asterisks indicate a difference of (P < 0.05) from control
value. All treatments were plated in triplicate for each experiment.
N values for each treatment group are given in parenthesis above
each column
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be performed simultaneously. It is also possible that the
effect of inhibition of AMPK in granulosa cells differs
between species such as cattle and humans, much the same
way as AMPK activation increases P4 in the chicken, but
not in rats or chickens. Therefore, it appears that stimu-
lated, but not basal P4 secretion, is regulated by AMPK in
human mural granulosa cells.
Data from Experiment 2 support the conclusion that
infertility type affects the ability of luteinized human
mural granulosa cells to respond in vitro to the luteotropic
factor, hCG. If these cells likewise failed to respond to hCG
in vivo it could lead to luteal insufficiency or even early
regression of the CL, resulting in pregnancy loss. Our
hypothesis is that the in vivo environments in which
granulosa cells develop contribute to their ability to re-
spond to hCG as they transition into a luteal phenotype.
Progesterone production after stimulation with hCG in
granulosa cells from endometriosis, unexplained, and
tubal factor patients was not different than basal P4 pro-
duction. Therefore, these patients were unable to respond
to stimulation by hCG, despite having normal basal P4
levels. However, as expected, granulosa cells from patients
with partners having male infertility exhibited a significant
increase in P4 production when compared to control
values. Clinically, all patients undergoing IVF treatments
are regularly given empirical supportive P4 after embryo
transfer, which eliminates the need for the patient’s
granulosa cells to increase P4 in response to embryo
derived hCG to sustain a pregnancy. However, using
mural granulosa cells to identify each patient’s ability to
naturally respond to hCG could allow for administration
of lower levels of exogenous P4. There is recent evidence
that supplemental P4 after the first positive β-hCG preg-
nancy test following IVF may not be necessary to achieve
a live birth [16]. Elimination of unnecessary P4 supple-
mentation could reduce cost and time requirements for
patients undergoing IVF.
A significant increase in P4 was seen in mural cells of
those women who became pregnant following IVF. In
contrast, P4 production in the hCG-stimulated treat-
ment group was not different from controls in the mural
cells of women who did not become pregnant following
IVF. Failure of these cells to secrete high levels of P4 in
vivo is similar to a condition known as luteal phase de-
fect [LPD]. In LPD there is only a brief elevation in P4
secretion (typically <11 days) after ovulation, and LPD is
reported to occur in up to 20% of women [2]. The mean
peak P4 level for women with short luteal phases was
Fig. 2 Progesterone production by granulosa cells from patients with different causes of infertility. Progesterone production by granulosa cells
from patients with male factor, endometriosis, other/unexplained, and tubal infertility before and after treatment with PGF2α (0.1 μg/ml) or hCG
(5 IU/ml). Asterisks indicate a difference of (P < 0.05) from control value within infertility group. N values for each treatment group are given in
parenthesis above each column
Fig. 3 Progesterone production by granulosa cells from patients of different ages. Patients who ranged in age from 25 to 29 years old did not
response to hCG with a significant increase in progesterone production. However, other age groups (30–35 and ≥36 years old) did have a
significant increase in progesterone when stimulated with hCG. Asterisks indicate a difference of (P < 0.05) from control value within age ranges.
Cells were treated with PGF2α (0.1 μg/ml) or hCG (5 IU/ml). N values for each treatment group are given in parenthesis above each column
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1.8 ng/ml compared to the mean peak P4 level of
7.6 ng/ml for women with normal luteal phase length
[21]. Interestingly, LPD has been associated with endomet-
riosis [8], polycystic ovarian syndrome [PCOS], obesity [10],
and aging [18]. These conditions differ significantly in their
etiology, however all have the potential to influence the
hormonal environment in which granulosa cells
develop and their ability to function as luteal cells. A
short luteal phase may be due to a defect in the process
of luteinization or P4 production, or both. Experiments 1
and 2 were performed prior to any luteal phase supplemen-
tation in these patients, and therefore the P4 production
would be a representation of their innate ability to respond
to physiological doses of hCG. The inability of these cells to
respond could potentially be explained by impaired choles-
terol transport mechanisms within the ovary, or a defi-
ciency in LH receptors. In addition, gene expression for
STAR, CYP11A1, and 3βHSD were all significantly reduced
in ewes that exhibited a short luteal phase during the non-
breeding season [5]. Stimulation of mural granulosa cells
with hCG and measurement of P4 levels on day 4 of cul-
ture, prior to day 5–6 blastocyst transfers, would determine
if hCG response was predictive of pregnancy success inde-
pendent of embryo quality.
It was not surprising that P4 production by mural
granulosa cells was affected by age and BMI, both of which
have previously been shown to alter steroid production in
vivo [9, 26]. Surprisingly, the age group that did not have
an increase in P4 production was the youngest age group.
It should be noted, however, that this group had the largest
numerical increase in P4 when stimulated with hCG. How-
ever, the fact that granulosa cells from two of the four pa-
tients responded which lead to highly variability, several
different causes of infertility (two tubal factor, endometri-
osis, male) and the small population size (n = 4) could sep-
arately or collectively account for the lack of difference
within this age group. In contrast, it was encouraging to see
that mural cells from older patients responded to luteo-
tropic hCG, suggesting that these cells are capable of in-
creases in P4, which are needed for a successful pregnancy.
Fig. 4 Progesterone production by granulosa cells from patients with different body mass indexes. Patients with normal body mass index [BMI]
(18.5–24.9) had a significant increase in progesterone production when treated with hCG (P < 0.0001). Cells of patients who were categorized as
overweight (BMI 25–29.9) or obese (BMI >30) did not have an increase in progesterone production when stimulated with hCG (P > 0.05).
Asterisks indicate a difference of (P < 0.05) from control value with BMI categories. Cells were treated with PGF2α (0.1 μg/ml) or hCG (5 IU/ml).
N values for each treatment group are given in parenthesis above each column
Fig. 5 Progesterone production by granulosa cells in non-pregnant versus pregnant patients. Progesterone production in mural granulosal cells
was affected by pregnancy status post in-vitro fertilization (IVF). Luteinized mural granulosa cells from patients who became pregnant to the IVF
cycle produced significantly more progesterone when stimulated with hCG than those who did not become pregnant (2.4 vs. 1.8 ng/ml;
P < 0.05). Asterisks indicate a difference of (P < 0.05) from control value with pregnancy outcome. Cells were treated with PGF2α (0.1 μg/ml) or
hCG (5 IU/ml). N values for each treatment group are given in parenthesis above each column
Bowdridge et al. Reproductive Biology and Endocrinology  (2017) 15:76 Page 6 of 8
Patients with BMIs in either the overweight or obese
range did not respond to hCG with increased P4 produc-
tion. However, due to the small patient number in the over-
weight (n = 6) and obese groups (n = 3) these results should
be interpreted cautiously. Nonetheless, combining the data
from these two groups to increase patient number still did
not result in a significant increase in hCG stimulated P4
production (p = 0.11). The interrelationship between nutri-
tional status and reproduction is complicated, and the
mechanisms connecting the two are not well defined. It will
be critical to ascertain if the mural cells of overweight and
obese patients have insufficient substrate to produce P4
when stimulated or if they are resistant to hCG despite
adequate substrate. In a recent study using non-human
primates, weight gain directly impaired P4-secretion, which
was accompanied by decreased mRNA expression for LH
receptor, P450scc, STAR and 3βHSD within the CL, sug-
gesting that obesity can directly affect CL function [13].
Conclusions
In summary, understanding how drugs such as AICAR,
DM, and other AMPK activators alter steroidogenic path-
ways in ovarian cells could lead to alternative or novel infer-
tility treatments. Human mural granulosa cells serve as a
valuable model for understanding how AMPK and its
downstream targets affect P4 production in steroidogenic
cells. Additionally, when stimulated with hCG, P4 produc-
tion by mural granulosa cells differed among main infertility
type, age, BMI, and pregnancy outcome. Investigating differ-
ences in basal and stimulated P4 concentrations amongst
such patients may also give insight into luteal steroidogene-
sis in an infertile population. In addition to basal and stimu-
lated P4 production, mRNA and protein levels of key
enzymes such as P450scc, StAR, and 3βHSD should be eval-
uated across age, BMI, pregnancy outcome, and infertility
type. Critically evaluating similarities and differences in
granulosa cell P4 production between the previously men-
tioned factors has the potential to increase successful full-
term gestations in patients undergoing IVF, and decrease
the incidence of miscarriages induced by luteal insufficiency.
Additional file
Additional file 1: Progestereone data from experiments 1 and 2.
(XLSX 16 kb)
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